Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

POPULATION COUNCIL's RU 486 NDA SUBMISSION EXPECTED WITHIN 16 MONTHS

Executive Summary

POPULATION COUNCIL's RU 486 NDA SUBMISSION EXPECTED WITHIN 16 MONTHS, FDA Commissioner Kessler testified at a May 16 hearing before Rep. Wyden's (D-Ore.) House Small Business/Regulation Subcommittee. "We have been told by the Population Council that they anticipate that [an] application will take between nine and 16 months to prepare," Kessler said. In a press conference preceding the hearing, HHS Secretary Shalala announced that Roussel Uclaf is donating its U.S. patent rights to the abortifacient RU 486 (mifepristone) to the New York City-based non-profit research organization.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel